Related Experiment Video

Updated: May 12, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Pharmacokinetic characterization of CK2 inhibitor CX-4945

You Hwa Son1, Jin Sook Song, Seong Hwan Kim

  • 1Laboratory of Translational Therapeutics, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong-gu, Daejeon, 305-600, Republic of Korea.

Archives of Pharmacal Research
|April 2, 2013
PubMed

Insights

CX-4945, a protein kinase CK2 inhibitor, shows promising pharmacokinetic properties for cancer treatment. It demonstrates high oral bioavailability and stability, suggesting potential as an effective anti-cancer drug.

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Development

Background:

  • Protein kinase CK2 (CK2) overexpression is linked to cancer cell survival and poor patient prognosis.
  • CX-4945 is an orally bioavailable, ATP-competitive inhibitor of CK2, known to impede cancer cell proliferation and angiogenesis.

Purpose of the Study:

  • To characterize the pharmacokinetic profile of CX-4945.
  • To evaluate the drug's metabolic stability, CYP450 interactions, hERG channel inhibition, cell permeability, and bioavailability.

Main Methods:

  • Assessed CX-4945 stability in human and rat liver microsomes.
  • Determined inhibition percentages across major CYP450 isoforms (1A2, 2C19, 3A4, 2C9, 2D6).
  • Evaluated hERG potassium channel inhibition, MDCK cell permeability, plasma protein binding, and bioavailability after intravenous and oral administration in rats.

Main Results:

  • CX-4945 exhibited high stability and low inhibition (<10%) of CYP1A2, 2C19, and 3A4, but considerable inhibition (~70%) of CYP2C9 and 2D6.
  • Low hERG channel inhibition rate, high MDCK cell permeability (>10 × 10⁻⁶ cm/s), and >98% plasma protein binding were observed.
  • Intravenous administration showed a Vss of 1.39 L/kg and low CL of 0.08 L/kg/h. Oral administration resulted in high bioavailability (>70%).

Conclusions:

  • CX-4945 possesses favorable pharmacokinetic properties, including high oral bioavailability and good stability.
  • The drug's pharmacokinetic profile, potentially linked to its high cell permeability, supports its potential as an orally administered anti-cancer therapeutic targeting CK2.

More Related Videos

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Pharmacokinetics: Overview01:10

Pharmacokinetics: Overview

Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...